Intranasal delivery of iron chelators and management of central nervous system disease
Frontiers in Pharmacology · 18.12.2025 · 16
DOI: 10.3389/fphar.2025.1709259 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 18.12.2025. Verfasst von Ruiying Cheng und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical and Nutritional Sciences, University of Massachusetts Lowell, Lowell, MA, United States. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 171 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Brain iron dyshomeostasis plays a critical role in the pathology of multiple central nervous system (CNS) disorders, including neurodegenerative and neuropsychiatric diseases. Iron chelators such as deferoxamine (DFO) and deferiprone (DFP) have demonstrated therapeutic potential in mitigating disease progression in these conditions. However, systemic administration is hindered by poor blood-brain barrier (BBB) permeability, dose-limiting toxicity, and poor patient compliance due to frequent dosing regimens. In recent years, intranasal (IN) drug delivery has emerged as a promising strategy to bypass the BBB, providing a direct nose-to-brain delivery route via olfactory and trigeminal pathways while minimizing systemic exposure. This review provides a comprehensive summary of the current status of iron chelation therapy for CNS disorders with a focus on pharmacokinetics, efficacy, and translational potential of IN administration. While IN DFO has been extensively studied in preclinical models of Alzheimer’s disease and stroke, recent developments have expanded the scope to other chelators such as DFP. We compare traditional systemic routes, including oral and intravenous, with intranasal administration, highlighting their respective advantages and limitations for CNS delivery. With ongoing advances in formulation and delivery technologies, IN iron chelators provide a promising alternative for the treatment of CNS disorders characterized by impaired iron homeostasis in the brain.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biomedical and Nutritional Sciences, University of Massachusetts Lowell, Lowell, MA, United States.
Zitieren
APA
Cheng, R., & Kim, J. (2025). Intranasal delivery of iron chelators and management of central nervous system disease. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1709259
Vancouver
Cheng R, Kim J. Intranasal delivery of iron chelators and management of central nervous system disease. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1709259
BibTeX
@article{Cheng2025,
author = {Cheng, Ruiying and Kim, Jonghan},
title = {Intranasal delivery of iron chelators and management of central nervous system disease},
journal = {Frontiers in Pharmacology},
year = {2025},
volume = {16},
doi = {10.3389/fphar.2025.1709259}
}
EUVIMED